+971 4 501 4000

Gulf Drug has announced the introduction of a new oncology unit to its medical equipment business portfolio

Gulf Drug has announced the introduction of a new oncology unit to its medical equipment business portfolio. The new oncology unit is designed to provide innovative, state-of-the-art cancer treatment and other oncology-related solutions.

The first product to be distributed in this unit is the proton therapy from Ion Beam Applications (IBA), which has been awarded to Gulf Drug to exclusively distribute in the region.

IBA prides itself for being the best beam therapy provider in the market, with more than 30 years of experience in developing proton therapy solutions.

Proton therapy is a form of radiation therapy that uses protons, rather than photons, to deliver precise doses of radiation to specific areas of the body. Unlike photon therapy, which is delivered in a single dose, proton therapy can be tailored to each individual patient’s needs. This allows for a more precise dose of radiation to be delivered, with fewer side effects. Proton therapy can also be used to treat tumors that are located in areas of the body that are difficult to reach with traditional radiation therapy, such as the brain and spine.

One of the major benefits of proton therapy is that it reduces the risk of radiation damage to healthy tissue surrounding the tumor. Protons can be directed to a specific area of the body and can be stopped at the edge of the tumor, reducing the amount of radiation that is absorbed by the healthy tissue. This reduces the risk of long-term side effects such as scarring and organ damage.

Proton therapy also offers benefits to physicians. The IBA proton therapy system's optimized workflow, ultrafast irradiation, 2D & 3D Imaging & 2.5D STEREOSCOPIC X-RAY, and 6D Patient positioner, provide physicians with the ability to precisely target the cancerous cells and deliver a more accurate dose of radiation. In addition, by using proton therapy, physicians can reduce the total number of treatments needed, allowing patients to receive the same amount of radiation in fewer visits. This can help reduce costs and improve patient experience.

More than 100,000 patients have been treated in IBA centers worldwide to this day and this number keeps growing. Gulf Drug is committed to providing the best possible care and services to its customers and is excited to introduce this new unit and proton therapy solution to the healthcare industry in the region.

Published By : Gulf Drug

Publishing Date : March 07, 2023